Hematopoiesis News Volume 3.40 | Oct 9 2012

LABORATORY RESEARCH

Signaling from the Sympathetic Nervous System Regulates Hematopoietic Stem Cell Emergence during Embryogenesis
Rearchers demonstrated that the production of functional and phenotypic hematopoietic stem cells (HSCs) in the aorta-gonads-mesonephros (AGM) is impaired in the absence of Gata3. Furthermore, they showed that this effect on HSC generation is secondary to the role of Gata3 in the production of catecholamines, the mediators of the sympathetic nervous system, thus making these molecules key components of the AGM HSC niche. [Cell Stem Cell] Abstract

Altered Hematopoiesis in Trisomy 21 as Revealed Through In Vitro Differentiation of Isogenic Human Pluripotent Cells
Human trisomy 21 pluripotent cells of various origins, human embryonic stem, and induced pluripotent stem cells, were differentiated in vitro as a model to recapitulate the effects of trisomy on hematopoiesis. [Proc Natl Acad Sci USA] Abstract

A Pathway from Leukemogenic Oncogenes and Stem Cell Chemokines to RNA Processing via THOC5
The authors showed previously that hematopoietic stem cells have an absolute requirement for THOC5 for survival and that THOC5 is phosphorylated on tyrosine 225 as a consequence of leukemogenic protein tyrosine kinase action. In this report, they investigated pathways for THOC5 phosphorylation to develop an understanding of THO complex modulation by tyrosine kinase oncogenes in leukemias. [Leukemia] Abstract

A Pivotal Role of Bone Remodeling in Granulocyte Colony Stimulating Factor Induced Hematopoietic Stem/Progenitor Cells Mobilization
The majority of hematopoietic stem/progenitor cells (HSPCs) reside in bone marrow surrounded by a specialized environment, which governs HSPC function. Scientists investigated the potential role of bone remodeling cells (osteoblasts and osteoclasts) in homeostasis and stress-induced hematopoietic stem/progenitor cell mobilization. [J Cell Physiol] Abstract

The Development of Macrophages from Human CD34⁺ Hematopoietic Stem Cells in Serum-Free Cultures is Optimized by IL-3 and SCF
Researchers refined the means by which large numbers of macrophages are obtained under serum-free conditions from hematopoietic precursors. [Cytokine] Abstract

Different Mechanisms Causing Loss of Mismatched Human Leukocyte Antigens in Relapsing t(6;11)(q27;q23) Acute Myeloid Leukemia after Haploidentical Transplantation
Mismatched human leukocyte antigens (HLAs) on leukemic cells can be targeted by donor T cells in HLA-mismatched/haploidentical stem cell transplantation. In two cases of acute myeloid leukemia with t(6;11)(q27;q23) abnormality presented, flow cytometry analysis showed a lack of HLA-A unshared between recipients and donors in relapsing leukemic cells after HLA-haploidentical transplantation. [Eur J Haematol] Abstract

CLINICAL RESEARCH

Cardiovascular Risk Factors in Hematopoietic Cell Transplantation (HCT) Survivors: Role in Development of Subsequent Cardiovascular Disease
Researchers examined the incidence and predictors of cardiovascular risk factors and subsequent cardiovascular disease in 1885 consecutive 1+ year survivors of HCT performed at City of Hope between 1995 and 2004. [Blood] Abstract | Press Release

The Use of Intravenous Antibiotics at the Onset of Neutropenia in Patients Receiving Outpatient-Based Hematopoietic Stem Cell Transplants
The authors report that prophylactic use of intravenous once-daily ceftriaxone in patients receiving outpatient based hematopoietic stem cell transplant (HSCT) is safe and may be particularly effective in patients receiving autologous HSCT. [PLoS One] Full Article

Latexin Is Down-Regulated in Hematopoietic Malignancies and Restoration of Expression Inhibits Lymphoma Growth
Researchers found that latexin was down-regulated in a variety of leukemia and lymphoma cell lines as well as in CD34⁺ cells from the blood and marrow of patients with hematological malignancies. [PLoS One]
Full Article

Fludarabine with Cytarabine Followed by Reduced-Intensity Conditioning and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Poor-Risk Chronic Lymphocytic Leukemia
Researchers concluded that the fludarabine and cytarabine-reduced intensity conditioning  protocol seems to be a promising approach to the treatment of poor-risk chronic lymphocytic leukemia with a high response rate of 93% and favorable progression-free survival and overall survival of 70 and 85% at 2 years after stem cell transplantation, respectively.[Ann Hetamol] Abstract

The Nobel Prize in Physiology or Medicine 2012: Sir John B. Gurdon, Shinya Yamanaka
Nobel Assembly at Karolinska Institutet has decided to award The Nobel Prize in Physiology or Medicine 2012 jointly to John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent. [Nobel Media AB] Press Release

LLS and Celgene Corporation Announce Partnership to Accelerate Blood Cancer Therapies
The Leukemia & Lymphoma Society (LLS) and Celgene Corporation announced a partnership to identify and fund promising blood cancer research projects. The collaboration will leverage LLS’s infrastructure for the identification and acceleration of innovative research at academic centers in priority research areas with significant unmet medical need. [The Leukemia & Lymphoma Society] Press Release

ARIAD Completes Rolling Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration
ARIAD Pharmaceuticals, Inc. announced it has completed the rolling submission of the New Drug Application for its investigational BCR-ABL inhibitor, ponatinib, to the U.S. Food and Drug Administration. ARIAD is seeking U.S. marketing approval of ponatinib in patients with resistant or intolerant chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. [ARIAD Pharmaceuticals, Inc.]
Press Release

DACOGEN^® Approved In the European Union for the Treatment of Acute Myeloid Leukemia
Janssen-Cilag International NV announced that the European Commission has approved the marketing authorisation for DACOGEN^® for the treatment of adult patients (age 65 years and above) with newly diagnosed de novo or secondary acute myeloid leukaemia, according to the World Health Organisation classification, who are not candidates for standard induction chemotherapy. [Johnson & Johnson Services, Inc.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Research Associate – Quality Assurance (University of California)

Postdoctoral Position – Mouse Stem Cell Biology (University of Alabama)

Postdoctoral Position – Stem Cells and Cancer (Tsinghua University)

Scientist, Postdoctoral and Research Associate Positions (University of Miami – Sylvester Comprehensive Cancer Center)

Postdoctoral Position – Impact of Inflammation on Hematopoiesis and Cancer (University of Murcia)

Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.